Skip to main content

AMCP Nexus 2025 Posters Main banner

Drug pricing, payment, and reimbursement

Drug pricing, payment, and reimbursement

Type here to filter the list

(124) Cost-Effectiveness of a Hypothetical Outpatient RSV Treatment for Elderly Patients in the United States
(125) Cost-effectiveness of epcoritamab vs glofitamab in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) after at least 2 lines of therapy in the United States
(126) Title: Cost-Effectiveness of Osimertinib for Consolidation in EGFR-Mutated Stage III NSCLC
(127) PDABs in Motion: Tracing the Development of State-Led Drug Cost Regulation
(128) Evaluating the Role of Drug Pricing Tiers in Shaping Healthcare Outcomes for Elderly Patients
(129) Cost Consequence Analysis of Hormonal Contraception in the United States
(130) Cost Consequence Analysis of Immediate Postpartum Contraception in the United States
(131) Impact of triptan insufficient response on medication use, health care utilization, and costs: a retrospective claims study
(132) Health care resource utilization and economic burden in patients cycling through multiple triptans for migraines: a retrospective analysis
(133) Suitability of Cost-Effectiveness Thresholds for Drug Reimbursement Decision-Making in the US Market
(134) Budget impact of Symbravo® (MoSEIC™ meloxicam and rizatriptan) to health plans in the United States for the acute treatment of migraine in adults
(135) Understanding State Medicaid Spending on Prescription Drugs: A 10-State Comprehensive Analysis of Net State Medicaid Drug Spending as Part of the Total Medicaid Budget
(136) Unmasking Alternative Funding Programs- Patient Outcomes and Prescription Journey
(137) Lower total cost of care of first-line fixed-duration venetoclax + obinutuzumab vs treat-to-progression Bruton’s tyrosine kinase inhibitor regimens in patients with chronic lymphocytic leukemia in the United States: a population-based model
(138) Forced Alternatives: The Impact of Alternative Funding Programs on Specialty Medication Access vs. Traditional Coverage
(139) Balancing promise and prudence : Addressing stakeholder concerns about the use of artificial intelligence for pricing and reimbursement
(140) Healthcare decision-maker insights on Academy of Managed Care Pharmacy Format Version 5.0 formulary dossiers
(141) Lipoprotein(a) and Testing Policies: A Health Plan Claims Analysis
(142) A Descriptive Study Comparing Artificial Intelligence (A.I.)-Driven Preferred Specialty Drug Network Versus Traditional Specialty Drug Network on Drug Costs in a Multi-State Regional Health Plan